Prolocor, Slingshot Bioscience Publish Paper on Prognostic Tool to Help Assess Thrombosis Risk
DAIC
SEPTEMBER 10, 2024
The results of our validation studies show this innovative test demonstrates outstanding intra (2 percent) and inter (10 percent) test variation, well below the current FDA guidance (25 percent)," said Dr. David Schneider Prolocor Co-Founder and Chief Science Officer. tim.hodson Tue, 09/10/2024 - 13:34 Sept. 5,2024 - Prolocor, Inc.
Let's personalize your content